Sheng‐Chieh Chou

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

Wen‐Chien Chou, Sheng‐Chieh Chou, Chieh‐Yu Liu et al. · Blood · 2011 · 323 citations · Full text

Life Sciences, Hematology, Oncology +14

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Johnny Mahlangu, Radosław Kaczmarek, Annette von Drygalski et al. · New England Journal of Medicine · 2023 · 191 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer

Chia‐Lun Wu, Jar‐Yi Ho, Sheng‐Chieh Chou et al. · Oncotarget · 2016 · 74 citations · Full text

Medicine, Cell Biology, Oncology +17

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

Bella Madan, Margareth C Ozelo, Priyanka Raheja et al. · Journal of Thrombosis and Haemostasis · 2024 · 60 citations · Full text

Medicine, Hematology, Molecular Medicine +13

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja et al. · Research and Practice in Thrombosis and Haemostasis · 2024 · 40 citations · Full text

Medicine, Hematology, Molecular Medicine +15